JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: A recent study also suggests that BCR-ABL-mediated signaling pathways in CML cells are controlled by JAK2 through direct phosphorylation of tyrosine 177 of BCR-ABL [58].